INBIOGEN Balance Sheet Health
Financial Health criteria checks 6/6
INBIOGEN has a total shareholder equity of ₩139.5B and total debt of ₩1.1B, which brings its debt-to-equity ratio to 0.8%. Its total assets and total liabilities are ₩144.3B and ₩4.8B respectively.
Key information
0.8%
Debt to equity ratio
₩1.07b
Debt
Interest coverage ratio | n/a |
Cash | ₩8.71b |
Equity | ₩139.47b |
Total liabilities | ₩4.83b |
Total assets | ₩144.30b |
Financial Position Analysis
Short Term Liabilities: A101140's short term assets (₩16.1B) exceed its short term liabilities (₩3.9B).
Long Term Liabilities: A101140's short term assets (₩16.1B) exceed its long term liabilities (₩938.8M).
Debt to Equity History and Analysis
Debt Level: A101140 has more cash than its total debt.
Reducing Debt: A101140's debt to equity ratio has reduced from 3.6% to 0.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A101140 has sufficient cash runway for 10 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: A101140 is forecast to have sufficient cash runway for 8 months based on free cash flow estimates, but has since raised additional capital.